FGX International becomes wholly-owned subsidiary of Essilor

NewsGuard 100/100 Score

FGX International Holdings Limited (Nasdaq: FGXI) (“FGX International”) announced that it has completed its merger with a subsidiary of Essilor International (“Essilor”) of Charenton-le-Pont, France.

“We are excited to be a part of Essilor and look forward to doing great things together”

FGX International shareholders received $19.75 per share in cash, for an aggregate value of approximately $575 million, including the repayment of FGX International debt of approximately $115 million. Upon completion of the merger, FGX International became a wholly-owned subsidiary of Essilor and its shares ceased to be publicly traded on the NASDAQ Global Select Market. Following the merger, FGX International will change its place of incorporation from the British Virgin Islands to the State of Delaware.

“We are excited to be a part of Essilor and look forward to doing great things together,” said Alec Taylor, FGX International’s Chief Executive Officer.

The world leader in ophthalmic optical products, Essilor International researches, develops, manufactures and markets around the world a wide range of lenses to correct myopia, hyperopia, presbyopia and astigmatism. Its flagship brands are Varilux®, Crizal®, Essilor®, Definity® and Xperio™. Based in France, the company reported consolidated revenue of €3.2 billion in 2009, with 34,700 employees and operations in 100 countries. For more information, please visit www.essilor.com.The Essilor share trades on the NYSE Euronext Paris market and is included in the CAC 40 index. Codes and symbols: ISIN: FR FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

Source FGX International Holdings Limited


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.